Brief: Galera Announces Oral Presentation At 2022 American Society Of Clinical Oncology (Asco) Annual Meeting Detailing Results From Phase 3 Roman Trial Of Avasopasem

Galera Therapeutics

27/05/2022 24:40

May 26 (Reuters) - Galera Therapeutics Inc  GRTX.O :
    * GALERA ANNOUNCES ORAL PRESENTATION AT 2022 AMERICAN
SOCIETY OF
CLINICAL ONCOLOGY (ASCO) ANNUAL MEETING DETAILING RESULTS FROM
PHASE 3 ROMAN TRIAL OF AVASOPASEM
    * GALERA THERAPEUTICS INC - ON TRACK TO SUBMIT NDA TO U.S.
FDA FOR
AVASOPASEM BY END OF 2022
    * GALERA THERAPEUTICS INC - RESULTS FROM 455-PATIENT PHASE 3
TRIAL
DEMONSTRATED A MEANINGFUL REDUCTION IN PATIENTS' SOM BURDEN
ACROSS MULTIPLE ENDPOINTS
    * GALERA THERAPEUTICS - RESULTS FROM 455-PATIENT PHASE 3
TRIAL
DEMONSTRATED STATISTICALLY SIGNIFICANT REDUCTIONS ON PRIMARY
ENDPOINT OF INCIDENCE OF SOM
    * GALERA THERAPEUTICS INC - RESULTS FROM 455-PATIENT PHASE 3
TRIAL
DEMONSTRATED SIGNIFICANT REDUCTIONS ON SECONDARY ENDPOINT OF
NUMBER OF DAYS OF SOM

Source text for Eikon:  ID:nGNX98K98k 
Further company coverage:  GRTX.O 

 ((Reuters.Briefs@thomsonreuters.com;))